SCHEMBL22857063

SCHEMBL22857063

CCN1CCC(NC(=O)CC(C)C)C(N)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RET P07949 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
TP53 P04637 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
KDM5A P29375 1/20 0.34
KDM4E B2RXH2 1/20 0.33
PREP P48147 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
DRD2 P14416 2/20 0.32
HTR2A P28223 2/20 0.32
DRD3 P35462 2/20 0.32
EPHX1 P07099 2/20 0.32
EPHX2 P34913 1/20 0.32
RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147984 0.88 RET (0.36) RETSMN1; SMN2TP53ALDH1A1KDM5A
SCHEMBL20070059 0.83 SMN1; SMN2 (0.38) RETSMN1; SMN2TP53ALDH1A1CCNA2
SCHEMBL20147533 0.82 RET (0.37) RETSMN1; SMN2TP53ALDH1A1KDM5A
SCHEMBL25444710 0.80 KDM5A (0.46) SMN1; SMN2TP53ALDH1A1CCNA2CDK2
SCHEMBL25122039 0.80 KDM5A (0.46) SMN1; SMN2TP53ALDH1A1CCNA2CDK2
SCHEMBL25122038 0.76 EPHX1 (0.48) SMN1; SMN2TP53CCNA2CDK2CCNA1
SCHEMBL20070140 0.75 SMN1; SMN2 (0.37) RETSMN1; SMN2TP53ALDH1A1KDM5A
SCHEMBL20147507 0.74 RET (0.35) RETSMN1; SMN2TP53ALDH1A1KDM5A
SCHEMBL20147955 0.71 TP53 (0.44) RETSMN1; SMN2TP53ALDH1A1CCNA2
SCHEMBL21344393 0.70 ACKR3 (0.35) SMN1; SMN2CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885SMN1; SMN2 646/4885TP53 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.